Triple Agonist — Next-Gen Peptide

Retatrutide Body Transformation:
Up to 30% Weight Loss — Preview with AI

Q: Is retatrutide better than Mounjaro or Ozempic?

Clinical data shows retatrutide produces substantially greater weight loss than both tirzepatide (Mounjaro) and semaglutide (Ozempic). Retatrutide achieves ~28% weight loss vs tirzepatide's ~22.5% and semaglutide's ~15%. Retatrutide is a triple agonist (GLP-1/GIP/glucagon) compared to tirzepatide's dual and semaglutide's single mechanism.

Q: What is the retatrutide dosing schedule?

Retatrutide is administered as a once-weekly subcutaneous injection. In clinical trials, the dose escalation schedule starts at 2mg and increases every 4 weeks: 2mg, 4mg, 6mg, 9mg, and up to the target dose of 12mg.

Retatrutide is the most powerful weight loss peptide ever tested in clinical trials. See what your body could look like at 1, 3, 6, or 12 months.

Key Takeaways (TRIUMPH-1 Phase 3 Data)

Average weight loss on retatrutide 12mg: 28.3% of body weight (70.3 lbs) over 80 weeks
Extension study showed up to 30.3% (85 lbs) at 104 weeks — approaching bariatric surgery results
Triple agonist mechanism targets GLP-1, GIP, and glucagon receptors simultaneously
Even the lowest dose (4mg) achieved 19% weight loss — more than Ozempic's maximum
45.3% of participants on 12mg achieved ≥30% weight loss

Preview Your Retatrutide Transformation

Upload a photo and see what triple-agonist peptide therapy could do for your body at 1, 3, 6, or 12 months.

What Is Retatrutide?

Retatrutide (LY3437943) is a first-in-class triple hormone receptor agonist developed by Eli Lilly. Unlike semaglutide (Ozempic), which targets only GLP-1 receptors, or tirzepatide (Mounjaro), which targets GLP-1 and GIP, retatrutide activates three receptors simultaneously:

GLP-1 — Reduces appetite and slows gastric emptying
GIP — Enhances insulin response and fat metabolism
Glucagon — Increases energy expenditure and promotes fat burning

This triple mechanism makes retatrutide the most potent weight loss medication ever studied in clinical trials, with results approaching those of bariatric surgery.

Retatrutide Weight Loss Timeline

Based on TRIUMPH-1 Phase 3 trial data (2,339 participants, 80 weeks), here is the expected weight loss timeline for someone starting at 250 lbs on the 12mg dose:

Timeline	Expected Weight Loss	Visual Changes
Month 1	5-8 lbs (2-3%)	Reduced bloating, strong appetite suppression, early face changes
Month 3	18-30 lbs (7-12%)	Noticeable face slimming, clothes 1-2 sizes smaller, energy increase
Month 6	35-55 lbs (14-22%)	Dramatic body shape change, visible jawline, new wardrobe needed
Month 12	55-75 lbs (22-30%)	Complete transformation, comparable to bariatric surgery results
Month 18+	Up to 85 lbs (30.3%)	Maximum effect, sustained weight maintenance

Retatrutide vs. Ozempic vs. Mounjaro: Head-to-Head

Retatrutide dramatically outperforms all existing GLP-1 medications in clinical trials. The triple-agonist mechanism unlocks a level of weight loss previously only achievable with surgery.

Metric	Ozempic	Mounjaro	Retatrutide
Avg weight loss	14.9%	22.5%	28.3%
Max observed	~17%	~25%	30.3%
Mechanism	GLP-1	GLP-1 + GIP	GLP-1 + GIP + Glucagon
Key trial	STEP-1	SURMOUNT-1	TRIUMPH-1
Manufacturer	Novo Nordisk	Eli Lilly	Eli Lilly
FDA status	Approved	Approved	Phase 3 complete

Use our GLP-1 & Peptide Weight Loss Calculator to compare projected timelines for all three medications based on your starting weight.

Retatrutide Dosing Schedule

Retatrutide is administered as a once-weekly subcutaneous injection. The dose escalation schedule from the TRIUMPH-1 trial:

Weeks	Dose	Phase
Weeks 1-4	2 mg	Initiation
Weeks 5-8	4 mg	Escalation
Weeks 9-12	6 mg	Escalation
Weeks 13-16	9 mg	Escalation
Week 17+	12 mg	Target / Maintenance

Frequently Asked Questions

How much weight can you lose on retatrutide?

In the Phase 3 TRIUMPH-1 trial, participants on retatrutide 12mg lost an average of 28.3% of their body weight (70.3 lbs) over 80 weeks. In the extension study, weight loss reached up to 30.3% (85 lbs) at 104 weeks. Even the lowest tested dose (4mg) achieved 19% weight loss — more than Ozempic's maximum.

Is retatrutide better than Mounjaro or Ozempic?

Based on clinical trial data, retatrutide produces substantially greater weight loss than both tirzepatide (Mounjaro, 22.5%) and semaglutide (Ozempic, 14.9%). The triple-agonist mechanism (GLP-1/GIP/glucagon) is more effective than the dual or single mechanisms of existing medications. However, retatrutide is not yet FDA-approved.

When will retatrutide be available?

Retatrutide completed its Phase 3 TRIUMPH-1 trial with positive results in 2025-2026. Eli Lilly is expected to seek FDA approval based on these results. If approved, it could become available by late 2026 or 2027. Until then, you can preview your potential results with BeforeAfterFit's AI visualization tool.

What is the retatrutide dosing schedule?

Retatrutide is a once-weekly injection. The dose starts at 2mg and escalates every 4 weeks through 4mg, 6mg, and 9mg to a target dose of 12mg. Full titration takes approximately 16-17 weeks.

Ready to See Your Retatrutide Transformation?

Preview what triple-agonist peptide therapy could do for your body. $1 to unlock HD.

Related Resources

Medical Disclaimer: BeforeAfterFit is a visualization and motivation tool only. It does not provide medical advice. Retatrutide is not yet FDA-approved for weight loss. Always consult your healthcare provider before starting any medication. Clinical trial results may not reflect individual outcomes.